GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » EV-to-FCF

GRFS (Grifols) EV-to-FCF : (As of Jul. 03, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Grifols EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Grifols's Enterprise Value is $20,142 Mil. Grifols's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $0 Mil. Therefore, Grifols's EV-to-FCF for today is .

The historical rank and industry rank for Grifols's EV-to-FCF or its related term are showing as below:

GRFS' s EV-to-FCF Range Over the Past 10 Years
Min: 27.95   Med: 47.65   Max: 193.53
Current: 34.46

During the past 13 years, the highest EV-to-FCF of Grifols was 193.53. The lowest was 27.95. And the median was 47.65.

GRFS's EV-to-FCF is ranked worse than
60.15% of 537 companies
in the Drug Manufacturers industry
Industry Median: 24.99 vs GRFS: 34.46

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-07-03), Grifols's stock price is $9.095. Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.212. Therefore, Grifols's PE Ratio (TTM) for today is 42.90.


Grifols EV-to-FCF Historical Data

The historical data trend for Grifols's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols EV-to-FCF Chart

Grifols Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.47 70.55 -22.96 -251.76 33.97

Grifols Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -251.76 - - 33.97

Competitive Comparison of Grifols's EV-to-FCF

For the Drug Manufacturers - General subindustry, Grifols's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Grifols's EV-to-FCF falls into.


;
;

Grifols EV-to-FCF Calculation

Grifols's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=20142.421/0
=

Grifols's current Enterprise Value is $20,142 Mil.
Grifols's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols  (NAS:GRFS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Grifols's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.095/0.212
=42.90

Grifols's share price for today is $9.095.
Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.212.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Grifols EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Grifols's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.